BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zunza M, Gray DM, Young T, Cotton M, Zar HJ. Isoniazid for preventing tuberculosis in HIV-infected children. Cochrane Database Syst Rev 2017;8:CD006418. [PMID: 28850172 DOI: 10.1002/14651858.CD006418.pub3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Jain A, Lodha R. Management of Latent Tuberculosis Infection in Children from Developing Countries. Indian J Pediatr 2019;86:740-5. [PMID: 30741387 DOI: 10.1007/s12098-019-02861-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 LaCourse SM, Richardson BA, Kinuthia J, Warr AJ, Maleche-Obimbo E, Matemo D, Cranmer LM, Escudero JN, Hawn TR, John-Stewart GC. Infant TB Infection Prevention Study (iTIPS): a randomised trial protocol evaluating isoniazid to prevent M. tuberculosis infection in HIV-exposed uninfected children. BMJ Open 2020;10:e034308. [PMID: 31969368 DOI: 10.1136/bmjopen-2019-034308] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Carvalho ACC, Cardoso CAA, Martire TM, Migliori GB, Sant'Anna CC. Epidemiological aspects, clinical manifestations, and prevention of pediatric tuberculosis from the perspective of the End TB Strategy. J Bras Pneumol 2018;44:134-44. [PMID: 29791553 DOI: 10.1590/s1806-37562017000000461] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
4 McArdle AJ, Turkova A, Cunnington AJ. When do co-infections matter? Curr Opin Infect Dis 2018;31:209-15. [PMID: 29698255 DOI: 10.1097/QCO.0000000000000447] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 12.5] [Reference Citation Analysis]
5 Dhungana GP, Thekkur P, Chinnakali P, Bhatta U, Pandey B, Zhang WH. Initiation and completion rates of isoniazid preventive therapy among people living with HIV in Far-Western Region of Nepal: a retrospective cohort study. BMJ Open 2019;9:e029058. [PMID: 31147370 DOI: 10.1136/bmjopen-2019-029058] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
6 LaCourse SM, Richardson BA, Kinuthia J, Warr AJ, Maleche-Obimbo E, Matemo D, Cranmer LM, Mecha J, Escudero JN, Hawn TR, John-Stewart G. A Randomized Controlled Trial of Isoniazid to Prevent Mycobacterium tuberculosis Infection in Kenyan Human Immunodeficiency Virus-Exposed Uninfected Infants. Clin Infect Dis 2021;73:e337-44. [PMID: 32564076 DOI: 10.1093/cid/ciaa827] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Reddy MM, Thekkur P, Ramya N, Kamath PBT, Shastri SG, Kumar RBN, Chinnakali P, Nirgude AS, Rangaraju C, Somashekar N, Kumar AMV. To start or to complete? - Challenges in implementing tuberculosis preventive therapy among people living with HIV: a mixed-methods study from Karnataka, India. Glob Health Action 2020;13:1704540. [PMID: 31937200 DOI: 10.1080/16549716.2019.1704540] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 MacPherson P, Lebina L, Motsomi K, Bosch Z, Milovanovic M, Ratsela A, Lala S, Variava E, Golub JE, Webb EL, Martinson NA. Prevalence and risk factors for latent tuberculosis infection among household contacts of index cases in two South African provinces: Analysis of baseline data from a cluster-randomised trial. PLoS One 2020;15:e0230376. [PMID: 32182274 DOI: 10.1371/journal.pone.0230376] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Lwevola P, Izudi J, Kimuli D, Komuhangi A, Okoboi S. Low level of tuberculosis preventive therapy incompletion among people living with Human Immunodeficiency Virus in eastern Uganda: A retrospective data review. J Clin Tuberc Other Mycobact Dis 2021;25:100269. [PMID: 34504952 DOI: 10.1016/j.jctube.2021.100269] [Reference Citation Analysis]
10 Amanullah F, Bacha JM, Fernandez LG, Mandalakas AM. Quality matters: Redefining child TB care with an emphasis on quality. J Clin Tuberc Other Mycobact Dis 2019;17:100130. [PMID: 31788571 DOI: 10.1016/j.jctube.2019.100130] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Ross JM, Badje A, Rangaka MX, Walker AS, Shapiro AE, Thomas KK, Anglaret X, Eholie S, Gabillard D, Boulle A, Maartens G, Wilkinson RJ, Ford N, Golub JE, Williams BG, Barnabas RV. Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data. Lancet HIV 2021;8:e8-e15. [PMID: 33387480 DOI: 10.1016/S2352-3018(20)30299-X] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Dodd PJ, Yuen CM, Becerra MC, Revill P, Jenkins HE, Seddon JA. Potential effect of household contact management on childhood tuberculosis: a mathematical modelling study. Lancet Glob Health 2018;6:e1329-38. [PMID: 30266570 DOI: 10.1016/S2214-109X(18)30401-7] [Cited by in Crossref: 33] [Cited by in F6Publishing: 17] [Article Influence: 11.0] [Reference Citation Analysis]
13 Mudzviti T, Shamu T, Chimbetete C, Munengerwa T, Bote S, Pascoe M. Tolerability of Isoniazid Preventive Therapy in an HIV-Infected Cohort of Paediatric and Adolescent Patients on Antiretroviral Therapy from a Resource-Limited Setting: A Retrospective Cohort Study. Drugs Real World Outcomes 2019;6:37-42. [PMID: 30758779 DOI: 10.1007/s40801-019-0147-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 González Fernández L, Casas EC, Singh S, Churchyard GJ, Brigden G, Gotuzzo E, Vandevelde W, Sahu S, Ahmedov S, Kamarulzaman A, Ponce-de-León A, Grinsztejn B, Swindells S. New opportunities in tuberculosis prevention: implications for people living with HIV. J Int AIDS Soc 2020;23:e25438. [PMID: 31913556 DOI: 10.1002/jia2.25438] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
15 Gatchalian SR, Agathis NT, Castillo-Carandang NT, Gunter SM, Murray KO, Mandalakas AM. Design and Evaluation of Risk Assessment Tools to Identify Pediatric Tuberculosis Infection in Bohol, the Philippines, a Low-HIV- and High-TB-Burden Setting. Am J Trop Med Hyg 2020;103:1818-26. [PMID: 32975174 DOI: 10.4269/ajtmh.20-0244] [Reference Citation Analysis]
16 Yirdaw KD, Teklu AM, Mamuye AT, Zewdu S. Breakthrough tuberculosis disease among people with HIV - Should we be worried? A retrospective longitudinal study. PLoS One 2019;14:e0211688. [PMID: 30716126 DOI: 10.1371/journal.pone.0211688] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]